Lakefront Biotherapeutics | GLPG - Operating Profit


Lakefront Biotherapeutics reported EUR-43.51M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
argenx SE USD 486M 7M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Genmab DKK 407M 182M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
GRIFOLS EUR 329M 80M Jun/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Incyte USD -707.47M 1.41B Sep/2026
Merck EUR 1.1B 51M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
UCB EUR 1.29B 571M Dec/2025
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026